Proteomic profiling of peritoneal rinse fluid sediment separates patients with ovarian cancer from women admitted for cesarean section. A pilot study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue 7, 2010, Pages 470-477

  Honoré, Bent ^a   Vorum, Henrik ^b   Knudsen, Aage ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarkers; Ovarian cancer; Proteomics; Tandem mass spectrometry; Two dimensional gel electrophoresis

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; FIBRINOGEN BETA; HAPTOGLOBIN; HAPTOGLOBIN ALPHA2; HAPTOGLOBIN BETA; PREALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; ASCITIC FLUID; CESAREAN SECTION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PATIENT ADMISSION; PILOT PROJECTS; PREGNANCY; PROTEOMICS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77958503767     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.508129     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Menon U. Ovarian cancer screening. CMAJ 2004;171: 323-324
3. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange proteinchips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343-12348
4. Zhang Z, Bast RC, Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identifi ed from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-5890
5. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006;12:432-441
6. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-577 (Pubitemid 34178440)
7. Rai AJ, Zhang Z, Rosenzweig J, Shih Ie M, Pham T, Fung ET, Sokoll LJ, Chan DW. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002;126:1518-1526
8. Yu JK, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B 2005;6:227-231
9. Jurisicova A, Jurisica I, Kislinger T. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev Proteomics 2008;5:551-560
10. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5: 4589-4596
11. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867
12. H onoré B, Ø s tergaard M, Vorum H. Functional genomics studied by proteomics. Bioessays 2004;26:901-915
13. Honoré B, Vorum H, Pedersen AE, Buus S, Claë sson MH. Changes in protein expression in p53 deleted spontaneous thymic lymphomas. Exp Cell Res 2004;295:91-101.
14. Lyngholm M, Vorum H, Nielsen K, Ø s tergaard M, Honoré B, Ehlers N. Differences in the protein expression in limbal versus central human corneal epithelium-a search for stem cell markers. Exp Eye Res 2008;87:96-105.
15. Ø stergaard M, Hansen GAW, Vorum H, Honoré B. Proteomic profi ling of fi broblasts reveals a modulating effect of extracellular calumenin on the organization of the actin cytoskeleton. Proteomics 2006;6:3509-3519
16. Honoré B, Buus S, Cla ë sson MH. Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53. Proteome Sci 2008;6:18.
17. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probabilitybased protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20:3551-3567
18. Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol 2007;29:92-110.
19. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008;199: 215-223
20. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profi ling and mass spectrometry. Clin Cancer Res 2003;9:2904-2911
21. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE. Phase ii biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010;136:1079-1088
22. Walsh CS, Karlan BY. Molecular signatures of ovarian cancer: from detection to prognosis. Mol Diagn Ther 2010;14:13-22.
23. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005;5:4625-4636
24. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE. Proteomic profi ling identifi es afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370-7379
25. Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010;31:599-610.
26. Ogata Y, Heppelmann CJ, Charlesworth MC, Madden BJ, Miller MN, Kalli KR, Cilby WA, Bergen HR, 3rd, Saggese DA, Muddiman DC. Elevated levels of phosphorylated fi brinogen-alpha-isoforms and differential expression of other post-translationally modifi ed proteins in the plasma of ovarian cancer patients. J Proteome Res 2006;5:3318-3325
27. Khan A, Packer NH. Simple urinary sample preparation for proteomic analysis. J Proteome Res 2006;5:2824-2838
28. Kang S, Shim HS, Lee JS, Kim DS, Kim HY, Hong SH, Kim PS, Yoon JH, Cho NH. Molecular proteomics imaging of tumor interfaces by mass spectrometry. J Proteome Res 2010;9:1157-1164
29. Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, Lee S, Lee C, Ko JJ, An HJ. Proteomic identification of overexpressed prdx 1 and its clinical implications in ovarian carcinoma. J Proteome Res 2010;9:451-457
30. Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St Onge P, Kireeva I, Schmitt-Ulms G, Brown TJ, Murphy J, Rosen B, Shaw P, Jurisica I, Kislinger T. A proteome resource of ovarian cancer ascites: Integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008;7:339-351
31. Jandu N, Richardson M, Singh G, Hirte H, Hatton MW. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fi brin that collectively possess an antiangiogenic property. Int J Gynecol Cancer 2006;16:1536-1544
32. Gericke B, Raila J, Sehouli J, Haebel S, Konsgen D, Mustea A, Schweigert FJ. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005;5:133.
33. Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med 2001;161:2733-2737
34. Zhao C, Annamalai L, Guo C, Kothandaraman N, Koh SC, Zhang H, Biswas A, Choolani M. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 2007;9:1-7.
35. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885-891
36. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867
37. Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, Camp DG, 2nd, Smith RD. Evaluation of multiprotein immunoaffi nity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006;5: 2167-2174
38. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-666